Atlas Trials

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Clinical trial NCT07388602 · RECRUITING

Trial details

NCT number
NCT07388602
Sponsor
Sinocelltech Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Amyloidosis
Start date
2026-01-08
Primary completion
2027-12-01
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.